When Eisai-Biogen Alzheimer's drug was approved on Friday, it became the second drug in about 20 years to be available to Alzheimer's patients.
There are still questions around Leqembi, the brand name for the drug generically known as lecanemab. How will Eisai and Biogen (Nasdaq: BIIB) commercialize it? What about safety issues following reports of brain bleeds? Is the $26,500-per-year price tag too high?
More on this story from Boston Business Journal
Get New England news, weather forecasts and entertainment stories to your inbox. Sign up for NECN newsletters.
Copyright Boston Business Journal
